From the publishers of JADPRO

HR+ HER2- Breast Cancer Resource Center

Advertisement

Redefining the Treatment Landscape: HER2-Low and Its Implications for HR+ HER2- Metastatic Breast Cancer

View all
FROM THE EDITORS

Welcome to the HR+ HER2- Breast Cancer Resource Center! We’re excited to present you with current information, news items, highlights from the literature, and other resources that focus on this disease space and the advanced practitioner’s role in delivering high-quality care to patients. If you have any feedback or questions, please contact jadpro-editor@conexiant.com.

Katie Newlin, RN, MSN, AGPCNP-BC

Washington University in St. Louis/Siteman Cancer Center

 

Kate Taucher, PharmD, MHA, BCOP, FASHP, FAPO, FHOPA

UCHealth Memorial Hospital

Resources

Intravenous Cancer Treatment Education

Abemaciclib AE Monitoring

Evidence-Based Approaches for the Management of Side-Effects of Adjuvant Endocrine Therapy in Patients with Breast Cancer

Real-world Risk of Recurrence by Nodal Status in Patients with HR+, HER2-, Node-positive, High-Risk Early Breast Cancer

Vaginal Estrogen Therapy Use and Survival in Females with Breast Cancer

News & Literature Highlights

Seminars in Nuclear Medicine

AI in breast cancer imaging: An update and future trends

Journal of Clinical Oncology

Adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer

Frontiers in Oncology

Real-world effectiveness of CDK4/6i in first-line treatment of HR+/HER2- advanced/metastatic breast cancer: Updated systematic review

Radiographics

Breast cancer surveillance in patients with a personal history of breast cancer: Updates and controversies

Cancer Treatment Reviews

First versus second-generation molecular profiling tests: How both can guide decision-making in early-stage hormone-receptor positive breast cancers?

npj Precision Oncology

Successful unconventional precision treatment of inflammatory hormone receptor-positive breast cancer guided by molecular profiling

BMC Women’s Health

Comparison of the efficacy and safety of docetaxel plus capecitabine versus docetaxel plus epirubicin for human epidermal growth factor 2 -negative breast cancer: A meta-analysis

The Breast

Awareness of genomic testing among patients with breast cancer in Europe

Breast Cancer Research and Treatment

PTEN inactivating mutations are associated with hormone receptor loss during breast cancer recurrence

Cancer Cell

CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety

Advertisement
Case Studies

Genetic Testing and Risk Intervention Based on Family History of Early-Onset Breast Cancer

First-Line Treatment for Metastatic ER+ HER2- Breast Cancer

Advertisement
Quizzes
Test your knowledge of genetic testing and risk intervention based on family history of early-onset breast cancer
Test your knowledge on HR-positive, HER2-negative breast cancer
Test your knowledge on first-line treatment for metastatic ER+ HER2- breast cancer